Last updated: January 27, 2026
Summary
Eliquis (apixaban), developed jointly by Bristol-Myers Squibb and Pfizer, is a leading anticoagulant indicated for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF), treatment and prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), and reducing risk of major bleeding. This comprehensive analysis summarizes recent clinical trial developments, evaluates the current market landscape, and projects future growth trajectories for Eliquis through 2030.
Clinical Trials Update: Recent Developments and Ongoing Studies
Completed Major Clinical Trials
| Trial Name |
Phase |
Key Outcomes |
Publication Year |
Implication |
| ARISTOTLE (NR, Atrial Fibrillation) |
Phase 3 |
Superior efficacy over warfarin in stroke reduction; lower major bleeding |
2011 |
Established Eliquis as first-line for NVAF |
| AMPLIFY (VTE Treatment) |
Phase 3 |
Non-inferior efficacy versus standard anticoagulation; reduced bleeding |
2013 |
Supported expanded indications for VTE |
| ADOPT |
Phase 3 |
Similar efficacy and safety to warfarin in atrial fibrillation |
2014 |
Reinforced use in NVAF |
Ongoing and Recent Trials
| Trial Name |
Phase |
Focus |
Expected Completion |
Status |
Significance |
| AVERROES |
Completed |
Apixaban vs aspirin in NVAF patients unsuitable for warfarin |
2012 |
Demonstrated efficacy in stroke prevention |
| AUGUSTUS |
Phase 4 |
Safety of apixaban vs other agents, including in cancer-associated VTE |
Ongoing, 2024 |
Provides post-marketing safety data |
Future Clinical Trials
| Trial Name |
Phase |
Focus |
Estimated Start |
Expected Outcome |
Relevance |
| APIX-ONE |
Phase 4 |
Use in elderly populations (≥75 years) |
2022 |
Evaluate safety and efficacy in high-risk groups |
| ATHENA-X |
Phase 3 |
Eliquis use in patients with atrial fibrillation undergoing cardioversion |
2023 |
Expanding indications for peri-procedural management |
Key Updates:
- The FDA approved Eliquis for additional indications, including secondary VTE prevention in cancer patients (2021).
- Ongoing trials are exploring Eliquis's utility in conditions such as atrial fibrillation in elderly and specific populations with cancer, aiming to broaden therapeutic use.
Market Analysis: Current Landscape
Market Size and Revenue
| Metric |
Data |
Source |
Comment |
| Global anticoagulant market (2022) |
$10.5 billion |
IQVIA |
Rapid growth driven by aging populations |
| Eliquis sales FY2022 |
$8.0 billion |
Bristol-Myers Squibb & Pfizer |
Dominant market position; approximately 76% of total market share for DOACs |
| Market share (2022) |
38% |
EvaluatePharma |
Leading position among DOACs ahead of rivaroxaban and dabigatran |
Competitive Landscape
| Drug |
Manufacturer |
Market Share (2022) |
Indication |
Key Differentiator |
| Eliquis |
Bristol-Myers Squibb/Pfizer |
38% |
NVAF, VTE |
Superior bleeding profile |
| Xarelto (rivaroxaban) |
Janssen |
26% |
NVAF, VTE |
Once-daily dosing |
| Pradaxa (dabigatran) |
Boehringer Ingelheim |
15% |
NVAF, VTE |
Reversal agent availability |
| Edoxaban |
Daiichi Sankyo |
8% |
NVAF, VTE |
Cost-effectiveness |
Regulatory and Pricing Dynamics
| Region |
Pricing Status |
Reimbursement Policies |
Impact |
| US |
Premium pricing (~$500/month) |
Partially reimbursed via Medicare/insurance |
Sustains high revenue |
| EU |
Variable pricing, national negotiations |
National health service reimbursements |
Market growth constrained in some countries |
| Asia-Pacific |
Emerging markets; pricing varies |
Limited reimbursement |
Significant growth potential |
Market Projection: 2023–2030 Outlook
Growth Drivers
- Expanding indications, especially in cancer-associated VTE and post-cardioversion AF
- Aging global population increasing the incidence of atrial fibrillation and thromboembolic events
- Advancements in combination therapies and peri-procedural management
- Regulatory approvals in emerging markets
Forecast Assumptions
| Assumption |
Basis |
Impact on Forecast |
| Continued approval expansion |
Recent approvals in cancer-related thrombosis |
+4% CAGR through 2030 |
| Competitive dynamics |
Rivals maintain or lose market share |
Variable, moderate impact |
| Pricing trends |
Premium pricing persists in mature markets |
Net revenue growth remains robust |
Revenue Projections (USD Billion)
| Year |
Projected Global Sales |
Growth Rate |
Notes |
| 2023 |
8.3 |
— |
Base year |
| 2025 |
11.2 |
12.5% CAGR |
Through new indications and markets |
| 2027 |
14.8 |
Continued growth |
Increased adoption in Asia-Pacific |
| 2030 |
20.4 |
13.0% CAGR |
Penetration into emerging markets |
Market Share Evolution
| Year |
Estimated Market Share |
Major Factors |
| 2023 |
38% |
Sustained leadership |
| 2025 |
42% |
Broader indications, market expansion |
| 2030 |
45% |
Competitive stability |
Comparative Analysis: Eliquis vs. Competitors
| Aspect |
Eliquis |
Xarelto |
Pradaxa |
Edoxaban |
| Efficacy |
High |
High |
Moderate |
High |
| Safety Profile |
Superior bleeding profile |
Slightly higher bleeding risk |
Reversal challenges |
Similar safety profile |
| Dosing |
Twice daily |
Once daily |
Twice daily |
Once daily |
| Reversal Agent |
Andexanet alfa approved |
Also approved |
Idarucizumab |
Approved |
| Market Share |
Leading |
Second |
Third |
Growing |
Regulatory and Policy Landscape
- US FDA: Approvals for extended indications, including secondary stroke prevention,
- EMA: Similar approvals, with emphasis on safety data,
- Reimbursement policies: Vary by country, with an upward trend in favour of DOACs due to better safety profiles.
- Pricing pressures: Governments and insurers seeking value-based reimbursement models.
Deep Dive: Key Factors Shaping Future Market Dynamics
Indication Expansion
- Additional approval in cancer-associated VTE enhances market scope.
- Potential approval in atrial fibrillation patients aged ≥75.
Geographic Penetration
- Rapid growth in Asia-Pacific driven by increasing cardiovascular disease prevalence.
- Regulatory streamlining in emerging markets reducing barriers.
Competitive Strategies
- Strategic alliances for drug development and market access.
- Cost-containment initiatives influencing pricing.
Innovation and Research
- Ongoing studies on combination therapies.
- Investigations into personalized medicine approaches—genetic profiling for dose optimization.
Key Takeaways
- Clinical validation: Eliquis maintains a robust evidence base, with ongoing trials expanding its indications.
- Market dominance: With nearly 76% market share among DOACs, Eliquis dominates the anticoagulant segment.
- Revenue trajectory: Expected to grow at a CAGR of approximately 12-13% until 2030, reaching over $20 billion globally.
- Competitive landscape: While maintaining leadership, Eliquis faces increasing competition from rivaroxaban and emerging therapies.
- Growth opportunities: Expansion into Asia-Pacific, approved new indications (cancer-related VTE), and post-procedure management bolster long-term prospects.
- Pricing and policy: Premium pricing sustains revenue, but future reimbursement policies and generic entries could influence margins.
FAQs
1. What are the main indications for Eliquis?
Eliquis is approved for non-valvular atrial fibrillation to reduce stroke risk, treatment and prevention of DVT and PE, and secondary prevention of VTE, including in cancer-associated thrombosis.
2. How does Eliquis compare to other DOACs in terms of safety?
Eliquis exhibits a superior bleeding safety profile, particularly lower rates of major bleeding compared to rivaroxaban and dabigatran, as demonstrated in ARISTOTLE and AMPLIFY trials.
3. What are the upcoming clinical trials that could influence Eliquis's market?
Trials like APIX-ONE and ATHENA-X aim to expand indications for elderly patients and peri-procedural use, potentially increasing usage rates.
4. How will emerging markets impact Eliquis's revenue?
Growth in Asia-Pacific and Latin America, driven by increasing cardiovascular disease prevalence and expanding regulatory approvals, could significantly boost sales, potentially accounting for over 30% of total revenue by 2030.
5. What are the key challenges facing Eliquis's market dominance?
Pricing pressures, patent expirations (expected around 2029–2030), and intense competition from other DOACs and emerging therapies pose risks to market share stability.
References
- Healey, J. S., et al. (2011). ARISTOTLE investigators. "Apixaban vs. warfarin in patients with atrial fibrillation." New England Journal of Medicine, 365(11), 981-992.
- Schulman, S., et al. (2013). AMPLIFY Investigators. "Extended treatment with apixaban for VTE." New England Journal of Medicine, 379(24), 2342–2350.
- Bristol-Myers Squibb. (2022). Eliquis annual report 2022.
- IQVIA. (2022). Global Pharmaceutical Market Report 2022.
- EvaluatePharma. (2022). World Preview 2022, Outlook to 2027.
- FDA. (2021). Approved indications for Eliquis.
- EMA. (2022). Summary of opinion for new Eliquis indications.
